ASSEMBLY BIOSCIENCES, INC.
ASMBNasdaq
$26.81
↑ +3.8%Jul 17 close · end-of-day
Price
1Y↑ +41.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$453.1M
Enterprise Value
$226.5M
P/E
335.1
P/S
6.4
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
-8.8%
Dividend Yield
—
Revenue (TTM)
$71.1M
Net Income (TTM)
-$6.4M
Free Cash Flow (TTM)
-$39.8M
Gross Margin
—
Operating Margin
-19.1%
Net Margin
-9.0%
ROE
-3.2%
ROIC
—
Debt / Equity
—
Net Cash
$226.6M
Return 1Y
+38.9%
Company profile
Assembly Biosciences, Inc. discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
- CEO
- John G. McHutchison
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- California
- Website
- assemblybio.com
Management & directors
- Bjorkquist Jeanette MPFO and PAO
- White Nicole SChief Manufacturing Officer
- Delaney William E IvChief Scientific Officer
- Gaggar AnujChief Medical Officer
- Okazaki Jason ACEO and President
Roles derived from SEC Form 4 filings.
Earnings
ASMB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.2M↓ -12.8%
Diluted EPS-$0.54↓ -53.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $79.1M | $6.3M | $0.00 | $7.2M | $28.5M | $72.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$64.8M | -$132.7M | -$94.1M | -$64.6M | -$45.4M | -$12.1M |
| Net income | -$62.2M | -$129.9M | -$93.1M | -$61.2M | -$40.2M | -$6.1M |
| Diluted EPS | — | -$3.00 | -$23.08 | -$13.38 | -$6.69 | -$0.55 |
| Operating cash flow | -$63.0M | -$93.4M | -$84.5M | $22.7M | -$51.1M | -$41.1M |
| Free cash flow | -$63.4M | -$96.5M | -$84.6M | $22.5M | -$51.1M | -$41.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -81.9% | -2121.7% | — | -902.5% | -159.3% | -16.8% |
| Net margin | -78.6% | -2076.4% | — | -854.8% | -140.9% | -8.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.5M | $6.8M | $7.4M | $9.4M | $9.6M | $10.8M | $42.5M | $8.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.2M | -$11.0M | -$11.5M | -$9.9M | -$11.1M | -$10.9M | $19.8M | -$11.4M |
| Net income | -$11.2M | -$9.6M | -$10.3M | -$8.8M | -$10.2M | -$9.2M | $22.1M | -$9.1M |
| Diluted EPS | -$1.98 | -$1.51 | -$1.54 | -$1.17 | -$1.33 | -$0.72 | $2.67 | -$0.54 |
| Operating cash flow | -$17.1M | -$15.2M | -$407,000.00 | -$23.4M | -$16.8M | -$15.1M | $14.2M | -$22.1M |
| Free cash flow | -$17.1M | -$15.2M | -$407,000.00 | -$23.4M | -$16.8M | -$15.2M | $14.2M | -$22.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -143.0% | -160.1% | -156.7% | -105.5% | -115.2% | -100.9% | 46.6% | -138.4% |
| Net margin | -130.7% | -140.4% | -140.5% | -93.6% | -105.9% | -85.2% | 52.0% | -110.5% |
Company news
Jun 8, 2026
Jun 5, 2026
May 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Bjorkquist Jeanette M· PFO and PAO | Sale | 29 | $23.25 | $674.25 | filing |
| 2026-05-26 | GILEAD SCIENCES INC | Award | 471,698 | $26.50 | $12.5M | filing |
| 2026-03-30 | Bjorkquist Jeanette M· PFO and PAO | Sale | 312 | $26.65 | $8,314.86 | filing |
| 2026-03-30 | White Nicole S· Chief Manufacturing Officer | Sale | 188 | $26.65 | $5,010.24 | filing |
| 2026-03-30 | Bjorkquist Jeanette M· PFO and PAO | Sale | 16 | $27.49 | $439.84 | filing |
| 2026-03-30 | White Nicole S· Chief Manufacturing Officer | Sale | 9 | $27.49 | $247.41 | filing |
| 2026-03-29 | White Nicole S· Chief Manufacturing Officer | Award | 26,000 | $0.00 | $0.00 | filing |
| 2026-03-29 | Gaggar Anuj· Chief Medical Officer | Award | 26,000 | $0.00 | $0.00 | filing |
| 2026-03-29 | Delaney William E IV· Chief Scientific Officer | Award | 26,000 | $0.00 | $0.00 | filing |
| 2026-03-29 | Okazaki Jason A· CEO and President | Award | 94,250 | $0.00 | $0.00 | filing |
| 2026-03-29 | Delaney William E IV· Chief Scientific Officer | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-03-29 | Gaggar Anuj· Chief Medical Officer | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-03-29 | White Nicole S· Chief Manufacturing Officer | Award | 14,000 | $0.00 | $0.00 | filing |
| 2026-03-29 | Bjorkquist Jeanette M· PFO and PAO | Award | 3,500 | $0.00 | $0.00 | filing |
| 2026-03-29 | Okazaki Jason A· CEO and President | Award | 50,750 | $0.00 | $0.00 | filing |
| 2026-03-29 | Bjorkquist Jeanette M· PFO and PAO | Award | 6,500 | $0.00 | $0.00 | filing |
| 2025-08-08 | GILEAD SCIENCES INC | Buy | 2,295,920 | — | — | filing |
| 2025-06-16 | Bjorkquist Jeanette M· PFO and PAO | Award | 300 | $0.00 | $0.00 | filing |
Latest 18 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.